#USA #Toronto #Alamar Biosciences #AAIC 2025 #pTau protein

Alamar Biosciences Showcases Innovative pTau Protein Data

On July 29, 2025, at the Alzheimer’s Association International Conference (AAIC) in Toronto, Alamar Biosciences introduced groundbreaking findings regarding pTau proteins derived from the brain, aiming to enhance early disease detection. This year's conference promises over 30 scientific presentations centered around their NULISA™ platform, which is designed to redefine biomarker detection in neurodegenerative diseases.

Alamar Biosciences has made significant strides in precise proteomics, addressing the urgent need for early detection techniques in diseases such as Alzheimer's. Their NULISA™ platform offers unmatched sensitivity and specificity, recognizing over 120 proteins linked to central nervous system disorders. This year’s conference marks the first public demonstration of robust clinical data obtained from pTau measurements, showcasing the platform's efficiency in detecting Alzheimer's years before diagnosis.

Dr. Yuling Luo, founding CEO of Alamar Biosciences, expressed the importance of their platform, stating, "The presentation of brain pTau data at AAIC highlights both the sensitivity and specificity of our NULISA platform and our team's commitment to advancing neurodegeneration biomarker development."

Key Highlights of the Presentation

During the presentation scheduled for 1:20 PM ET on July 28, eminent speakers including Professor Jonathan Schott from University College London and Dr. Cheryl Wellington from the University of British Columbia will delve into specific findings that include:

1. Results of Brain pTau Proteins:
The findings will showcase results from a cohort of individuals born in 1946, highlighting levels of new brain pTau isoforms assayed through the NULISAseq™ CNS Disease Panel 120. It demonstrates the capability of pTau proteins in predicting Alzheimer’s disease several years pre-diagnosis.

2. Correlation with Disease Progression:
Data correlating levels of brain pTau with PET imaging outcomes, focusing on amyloid plaques and tau proteins showcased the potential for predictive insights in disease progression.

3. Neuropathology Biomarkers in Alzheimer’s Comorbidities:
Analysis from a unique cohort of patients with post-mortem confirmed pathologies helped identify biomarkers for neuropathologies and comorbidities associated with Alzheimer’s disease.

4. Preclinical Research Capabilities:
The NULISAseq™ Mouse Panel 120 has proven effective in analyzing plasma and brain homogenate samples from multiple Alzheimer’s disease clinical models.

The Alzheimer’s Association International Conference (AAIC) is recognized as a premier global forum for the scientific community, dedicated to dementia and Alzheimer’s research. Occurring annually, it attracts leading experts, scientists, and healthcare stakeholders who share the latest discoveries, foster collaborations, and accelerate the search for effective diagnostic and treatment options.

About Alamar Biosciences

Alamar Biosciences is a private life sciences firm committed to precision proteomics for early disease detection. Its proprietary NULISA technology and ARGO HT system work synergistically with the latest genomic advancements, achieving detection sensitivity in the attomolar range. This positions them significantly ahead of existing protein detection technologies. For more information, visit alamarbio.com.

For a complete list of posters and presentations featuring NULISA results at the AAIC conference, click here.